It is announced that the 'strong immune response' of the new corona vaccine was also seen in the elderly


VCU Capital News Service

As people get older, their immune system weakens, so the risk of severe coronavirus infection (COVID-19) increases in older people. For this reason, there is an urgent need to develop a vaccine that is highly effective for the elderly, but Oxford University and AstraZeneca, a pharmaceutical company, have newly announced that the vaccine under development has the same immunity from the elderly to the young. Announced that a primary response was obtained.

Vaccine hopes rise as Oxford jab prompts immune response among old as well as young adults | Reuters idUSKBN27B0IV

AstraZeneca: Our coronavirus vaccine triggers adult immune response

Covid-19 news: Oxford vaccine produces immune response in older people | New Scientist

As of July 2020, the vaccine ' AZD1222 ' under development by Oxford University and AstraZeneca had already been recognized as a 'strong immune response' to young people aged 18-55 . A spokeswoman for AstraZeneca said, 'It is encouraging to see immunogenic reactions and fewer side effects in older people who are more likely to have COVID-19 as well as younger people.' Provides further evidence of the immunogenicity and safety of AZD1222. ' The results of this research have not been published as a paper at the time of writing the article, but it is scheduled to be published in a scientific journal soon.

AstraZeneca has signed contracts with governments and companies to manufacture and supply vaccines when the results of late-stage clinical trials are nearing reporting, and initial vaccine distribution will take place at hospitals in London, England. In response, British Health Minister Matt Hancock announced on October 26 that the COVID-19 vaccine would be ready for distribution by the end of 2020 and is expected to be ready in the first half of 2021. He said he did not deny the possibility that vaccine distribution will start to some people in 2020.

Anthony Fauci, who leads the COVID-19 countermeasures in the United States as the director of the National Institute of Allergy and Infectious Diseases, also said that the efficacy and safety of the COVID-19 vaccine under development will be as early as November and at the latest in December. States to turn out. For this reason, it is expected that the focus will be on how to distribute the developed vaccines in the future.

in Science, Posted by darkhorse_log